In vitro and in vivo activities of hpi1, a selective antimicrobial against helicobacter pylori

Ekaterina Gavrish, Binu Shrestha, Chao Chen, Ida Lister, E. Jeffrey North, Lei Yang, Richard E. Lee, Angel Han, Bronwyn Williams, David Charnuska, Ken Coleman, Kim Lewis, Michael D. LaFleura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A high-throughput screen (HTS) was performed to identify molecules specifically active against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Currently, treatment of H. pylori infection is suboptimal, with failure rates approaching 25%, despite triple therapy with two broad-spectrum antibiotics and a proton pump inhibitor or quadruple therapy with added bismuth. The HTS was performed in 384-well plates, and reduction of the metabolic indicator resazurin was used as a reporter for cell growth. Diverse molecules from commercial sources were identified as hits, and in vitro validations included measurements of MIC and time-dependent killing as well as anaerobic susceptibility testing against a panel of gut microbes. In vivo validation included testing in the mouse model of H. pylori infection. The small molecule HPi1 (3-hydrazinoquinoxaline-2- thiol) had excellent potency, with an MIC of 0.08 to 0.16 g/ml and good selectivity for H. pylori compared to a panel of commensal bacteria. HPi1 was also effective in a mouse model of H. pylori infection, reducing colony counts to below the limit of detection after oral dosing of 25 mg/kg/day for 3 days. HPi1 is a promising lead in the search for more effective and specific H. pylori therapeutics.

Original languageEnglish
Pages (from-to)3255-3260
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Helicobacter pylori
Helicobacter Infections
Bismuth
Proton Pump Inhibitors
Peptic Ulcer
Sulfhydryl Compounds
Limit of Detection
In Vitro Techniques
Stomach
Therapeutics
Anti-Bacterial Agents
Bacteria
Carcinoma
Growth

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases
  • Medicine(all)

Cite this

In vitro and in vivo activities of hpi1, a selective antimicrobial against helicobacter pylori. / Gavrish, Ekaterina; Shrestha, Binu; Chen, Chao; Lister, Ida; North, E. Jeffrey; Yang, Lei; Lee, Richard E.; Han, Angel; Williams, Bronwyn; Charnuska, David; Coleman, Ken; Lewis, Kim; LaFleura, Michael D.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 6, 2014, p. 3255-3260.

Research output: Contribution to journalArticle

Gavrish, E, Shrestha, B, Chen, C, Lister, I, North, EJ, Yang, L, Lee, RE, Han, A, Williams, B, Charnuska, D, Coleman, K, Lewis, K & LaFleura, MD 2014, 'In vitro and in vivo activities of hpi1, a selective antimicrobial against helicobacter pylori', Antimicrobial Agents and Chemotherapy, vol. 58, no. 6, pp. 3255-3260. https://doi.org/10.1128/AAC.02573-13
Gavrish, Ekaterina ; Shrestha, Binu ; Chen, Chao ; Lister, Ida ; North, E. Jeffrey ; Yang, Lei ; Lee, Richard E. ; Han, Angel ; Williams, Bronwyn ; Charnuska, David ; Coleman, Ken ; Lewis, Kim ; LaFleura, Michael D. / In vitro and in vivo activities of hpi1, a selective antimicrobial against helicobacter pylori. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 6. pp. 3255-3260.
@article{013e24b64e4943fb917f5d6debcf0d05,
title = "In vitro and in vivo activities of hpi1, a selective antimicrobial against helicobacter pylori",
abstract = "A high-throughput screen (HTS) was performed to identify molecules specifically active against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Currently, treatment of H. pylori infection is suboptimal, with failure rates approaching 25{\%}, despite triple therapy with two broad-spectrum antibiotics and a proton pump inhibitor or quadruple therapy with added bismuth. The HTS was performed in 384-well plates, and reduction of the metabolic indicator resazurin was used as a reporter for cell growth. Diverse molecules from commercial sources were identified as hits, and in vitro validations included measurements of MIC and time-dependent killing as well as anaerobic susceptibility testing against a panel of gut microbes. In vivo validation included testing in the mouse model of H. pylori infection. The small molecule HPi1 (3-hydrazinoquinoxaline-2- thiol) had excellent potency, with an MIC of 0.08 to 0.16 g/ml and good selectivity for H. pylori compared to a panel of commensal bacteria. HPi1 was also effective in a mouse model of H. pylori infection, reducing colony counts to below the limit of detection after oral dosing of 25 mg/kg/day for 3 days. HPi1 is a promising lead in the search for more effective and specific H. pylori therapeutics.",
author = "Ekaterina Gavrish and Binu Shrestha and Chao Chen and Ida Lister and North, {E. Jeffrey} and Lei Yang and Lee, {Richard E.} and Angel Han and Bronwyn Williams and David Charnuska and Ken Coleman and Kim Lewis and LaFleura, {Michael D.}",
year = "2014",
doi = "10.1128/AAC.02573-13",
language = "English",
volume = "58",
pages = "3255--3260",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - In vitro and in vivo activities of hpi1, a selective antimicrobial against helicobacter pylori

AU - Gavrish, Ekaterina

AU - Shrestha, Binu

AU - Chen, Chao

AU - Lister, Ida

AU - North, E. Jeffrey

AU - Yang, Lei

AU - Lee, Richard E.

AU - Han, Angel

AU - Williams, Bronwyn

AU - Charnuska, David

AU - Coleman, Ken

AU - Lewis, Kim

AU - LaFleura, Michael D.

PY - 2014

Y1 - 2014

N2 - A high-throughput screen (HTS) was performed to identify molecules specifically active against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Currently, treatment of H. pylori infection is suboptimal, with failure rates approaching 25%, despite triple therapy with two broad-spectrum antibiotics and a proton pump inhibitor or quadruple therapy with added bismuth. The HTS was performed in 384-well plates, and reduction of the metabolic indicator resazurin was used as a reporter for cell growth. Diverse molecules from commercial sources were identified as hits, and in vitro validations included measurements of MIC and time-dependent killing as well as anaerobic susceptibility testing against a panel of gut microbes. In vivo validation included testing in the mouse model of H. pylori infection. The small molecule HPi1 (3-hydrazinoquinoxaline-2- thiol) had excellent potency, with an MIC of 0.08 to 0.16 g/ml and good selectivity for H. pylori compared to a panel of commensal bacteria. HPi1 was also effective in a mouse model of H. pylori infection, reducing colony counts to below the limit of detection after oral dosing of 25 mg/kg/day for 3 days. HPi1 is a promising lead in the search for more effective and specific H. pylori therapeutics.

AB - A high-throughput screen (HTS) was performed to identify molecules specifically active against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Currently, treatment of H. pylori infection is suboptimal, with failure rates approaching 25%, despite triple therapy with two broad-spectrum antibiotics and a proton pump inhibitor or quadruple therapy with added bismuth. The HTS was performed in 384-well plates, and reduction of the metabolic indicator resazurin was used as a reporter for cell growth. Diverse molecules from commercial sources were identified as hits, and in vitro validations included measurements of MIC and time-dependent killing as well as anaerobic susceptibility testing against a panel of gut microbes. In vivo validation included testing in the mouse model of H. pylori infection. The small molecule HPi1 (3-hydrazinoquinoxaline-2- thiol) had excellent potency, with an MIC of 0.08 to 0.16 g/ml and good selectivity for H. pylori compared to a panel of commensal bacteria. HPi1 was also effective in a mouse model of H. pylori infection, reducing colony counts to below the limit of detection after oral dosing of 25 mg/kg/day for 3 days. HPi1 is a promising lead in the search for more effective and specific H. pylori therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84901269549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901269549&partnerID=8YFLogxK

U2 - 10.1128/AAC.02573-13

DO - 10.1128/AAC.02573-13

M3 - Article

C2 - 24687512

AN - SCOPUS:84901269549

VL - 58

SP - 3255

EP - 3260

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -